세계의 에어로졸 약물전달 장비 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 유통 채널별, 지역별 부문 예측(2025-2030년)

Aerosol Drug Delivery Devices Market Growth & Trends:

The global aerosol drug delivery devices market size is anticipated to reach USD 62.1 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a notable CAGR of 13.16% from 2025 to 2030. Major factors driving the market growth include the rising prevalence of respiratory diseases, increasing healthcare awareness, advancements in inhaler technology, and the growing demand for home-based treatments.

The market growth is driven by the increasing prevalence of respiratory diseases such as COPD, asthma, and cystic fibrosis, a growing focus on portable inhalation devices, and the need for quick, effective treatments. Other factors include government awareness campaigns, an aging population, technological advancements, higher device adoption, urbanization, pollution, and increased R&D.

Innovation in the market focuses on developing eco-friendly fuels, improving user-interface designs for better patient adherence, and using AI for personalized diagnostics and treatment. Research into biodegradable materials could provide sustainable alternatives for device construction. The market is competitive and fragmented, with rapid technological progress driving constant change. Companies proactively embrace trends, focusing on patient-centered, environmentally friendly solutions to seize growth opportunities.

Moreover, key players in the market, such as AptarGroup, Inc., Koninklijke Philips N.V., AstraZeneca, and Novartis AG, among others, are engaging in strategic initiatives such as partnerships, collaborations, new product launches, acquisitions, and expansions to strengthen their market position. For instance, in January 2024, Kindeva Drug Delivery announced the acquisition of Summit Biosciences, a company specializing in intranasal drug delivery.

"Nasal drug delivery is becoming a preferred dosage format for a growing number of indications, as it allows users to non-invasively administer medications in an acute or emergency setting. Summit brings a differentiated understanding of how to effectively formulate drugs for nasal delivery and the capability to manufacture them at commercial scale. This addition not only fits Kindeva's ambition to be a global leader in the drug-device combination products CDMO market but also expands the toolbox we can offer our customers to help improve patient outcomes and experience of care globally."

Kindeva CEO Milton Boyer.

Aerosol Drug Delivery Devices Market Report Highlights:

• Based on type, the inhaler segment dominated the market with a revenue share of 89.59% in 2024 and is expected to witness the fastest growth at a CAGR over the forecast period owing to the advancement the development of technologically advanced products, and the growing adoption of digital solutions in the healthcare sector.
• Based on application, the COPD segment held the largest market share in 2024 and is anticipated to be the fastest-growing segment over the forecast period owing to the rising increasing prevalence worldwide.
• Based on the distribution channel, the institutional pharmacies segment held the largest market share in 2024, driven by the increasing need for bulk medication distribution, and the expanding patient population with respiratory conditions.
• North America dominated the aerosol drug delivery devices industry with a market share of 39.49% in 2024, owing to the advanced healthcare infrastructure, increasing geriatric population, and technological advancements.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.1.2. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. Distribution Channel Outlook
  • 2.2.4. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Aerosol Drug Delivery Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Industry Analysis
  • 3.2.1. User Perspective Analysis
  • 3.2.2. Key End Users
• 3.3. Technology Outlook
• 3.4. Regulatory Framework
• 3.5. Market Dynamics
  • 3.5.1. Market Drivers Analysis
    • 3.5.1.1. Rising prevalence of respiratory diseases
    • 3.5.1.2. Technological advancements
    • 3.5.1.3. Rising geriatric population
    • 3.5.1.4. Increasing awareness of self-medication and home healthcare
  • 3.5.2. Market Restraints Analysis
    • 3.5.2.1. High cost of devices
  • 3.5.3. Industry Challenges and Opportunity Analysis
• 3.6. Aerosol Drug Delivery Devices Market Analysis Tools
  • 3.6.1. Porter's Analysis
    • 3.6.1.1. Bargaining power of the suppliers
    • 3.6.1.2. Bargaining power of the buyers
    • 3.6.1.3. Threats of substitution
    • 3.6.1.4. Threats from new entrants
    • 3.6.1.5. Competitive rivalry
  • 3.6.2. PESTEL Analysis
    • 3.6.2.1. Political landscape
    • 3.6.2.2. Economic and Social landscape
    • 3.6.2.3. Technological landscape
    • 3.6.2.4. Environmental landscape
    • 3.6.2.5. Legal Landscape
• 3.7. Impact of COVID-19

Chapter 4. Aerosol Drug Delivery Devices Market: Type Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Type Market Share Analysis, 2024 & 2030
• 4.3. Segment Dashboard
• 4.4. Aerosol Drug Delivery Devices Market: By Type, 2018 to 2030
  • 4.4.1. Nebulizers
    • 4.4.1.1. Nebulizers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.1.2. Jet
      • 4.4.1.2.1. Jet Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.1.3. Mesh
      • 4.4.1.3.1. Mesh Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.1.4. Active
      • 4.4.1.4.1. Active Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.1.5. Passive
      • 4.4.1.5.1. Passive Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.1.6. Ultrasonic
      • 4.4.1.6.1. Ultrasonic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Inhaler
    • 4.4.2.1. Inhaler Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2.2. Pressurized Metered-Dose Inhaler (PMDI)
      • 4.4.2.2.1. Pressurized Metered-Dose Inhaler (PMDI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2.3. Dry-Powder Inhaler (DPI)
      • 4.4.2.3.1. Dry-Powder Inhaler (DPI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Aerosol Drug Delivery Devices Market: Application Estimates & Trend Analysis

• 5.1. Definition and Scope
• 5.2. Application Market Share Analysis, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. Aerosol Drug Delivery Devices Market: By Application, 2018 to 2030
  • 5.4.1. Asthma
    • 5.4.1.1. Asthma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 5.4.2.1. Chronic Obstructive Pulmonary Disease (COPD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Aerosol Drug Delivery Devices Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Definition and Scope
• 6.2. Distribution Channel Market Share Analysis, 2024 & 2030
• 6.3. Segment Dashboard
• 6.4. Aerosol Drug Delivery Devices Market: By Distribution Channel, 2018 to 2030
  • 6.4.1. Retail Pharmacies
    • 6.4.1.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Institutional Pharmacies
    • 6.4.2.1. Institutional Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Online Pharmacies
    • 6.4.3.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Aerosol Drug Delivery Devices Market: Regional Estimates & Trend Analysis by Region, Type, Application, Distribution Channel

• 7.1. Definition and Scope
• 7.2. Regional Market Share Analysis, 2024 & 2030
• 7.3. Regional Market Dashboard
• 7.4. Regional Market Snapshot
• 7.5. SWOT Analysis
  • 7.5.1. North America
  • 7.5.2. Europe
  • 7.5.3. Asia Pacific
  • 7.5.4. Latin America
  • 7.5.5. Middle East & Africa
• 7.6. Aerosol Drug Delivery Devices Market Share, By Region, 2024 & 2030, USD Million
• 7.7. North America
  • 7.7.1. North America Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. U.S.
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. U.S. Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Canada
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Canada Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. Mexico
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.7.4.3. Competitive Insights
    • 7.7.4.4. Canada Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Europe
  • 7.8.1. Europe Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. UK
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. UK Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Germany
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Germany Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. France
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. France Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Italy
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Italy Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.6. Spain
    • 7.8.6.1. Key Country Dynamics
    • 7.8.6.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.6.3. Competitive Insights
    • 7.8.6.4. Spain Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.7. Sweden
    • 7.8.7.1. Key Country Dynamics
    • 7.8.7.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.7.3. Competitive Insights
    • 7.8.7.4. Sweden Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.8. Denmark
    • 7.8.8.1. Key Country Dynamics
    • 7.8.8.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.8.3. Competitive Insights
    • 7.8.8.4. Sweden Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.9. Norway
    • 7.8.9.1. Key Country Dynamics
    • 7.8.9.2. Regulatory Landscape/Reimbursement Scenario
    • 7.8.9.3. Competitive Insights
    • 7.8.9.4. Sweden Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Asia Pacific
  • 7.9.1. Asia Pacific Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.2. China
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.9.2.3. Competitive Insights
    • 7.9.2.4. China Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.3. Japan
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.9.3.3. Competitive Insights
    • 7.9.3.4. Japan Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.4. India
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.9.4.3. Competitive Insights
    • 7.9.4.4. India Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.5. South Korea
    • 7.9.5.1. Key Country Dynamics
    • 7.9.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.9.5.3. Competitive Insights
    • 7.9.5.4. South Korea Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.6. Australia
    • 7.9.6.1. Key Country Dynamics
    • 7.9.6.2. Regulatory Landscape/Reimbursement Scenario
    • 7.9.6.3. Competitive Insights
    • 7.9.6.4. Australia Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.7. Thailand
    • 7.9.7.1. Key Country Dynamics
    • 7.9.7.2. Regulatory Landscape/Reimbursement Scenario
    • 7.9.7.3. Competitive Insights
    • 7.9.7.4. Thailand Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.10. Latin America
  • 7.10.1. Latin America Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10.2. Brazil
    • 7.10.2.1. Key Country Dynamics
    • 7.10.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.10.2.3. Competitive Insights
    • 7.10.2.4. Brazil Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10.3. Argentina
    • 7.10.3.1. Key Country Dynamics
    • 7.10.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.10.3.3. Competitive Insights
    • 7.10.3.4. Argentina Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.11. Middle East and Africa
  • 7.11.1. Middle East and Africa Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.11.2. South Africa
    • 7.11.2.1. Key Country Dynamics
    • 7.11.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.11.2.3. Competitive Insights
    • 7.11.2.4. South Africa Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.11.3. Saudi Arabia
    • 7.11.3.1. Key Country Dynamics
    • 7.11.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.11.3.3. Competitive Insights
    • 7.11.3.4. Saudi Arabia Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.11.4. UAE
    • 7.11.4.1. Key Country Dynamics
    • 7.11.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.11.4.3. Competitive Insights
    • 7.11.4.4. UAE Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.11.5. Kuwait
    • 7.11.5.1. Key Country Dynamics
    • 7.11.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.11.5.3. Competitive Insights
    • 7.11.5.4. UAE Aerosol Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Market Share Analysis
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Product Launches
  • 8.5.5. Research And Development
• 8.6. Company Profiles
  • 8.6.1. AptarGroup, Inc.
    • 8.6.1.1. Participant's Overview
    • 8.6.1.2. Financial Performance
    • 8.6.1.3. Product Benchmarking
    • 8.6.1.4. Recent Developments
  • 8.6.2. Koninklijke Philips N.V.
    • 8.6.2.1. Participant's Overview
    • 8.6.2.2. Financial Performance
    • 8.6.2.3. Product Benchmarking
    • 8.6.2.4. Recent Developments
  • 8.6.3. AstraZeneca
    • 8.6.3.1. Participant's Overview
    • 8.6.3.2. Financial Performance
    • 8.6.3.3. Product Benchmarking
    • 8.6.3.4. Recent Developments
  • 8.6.4. Novartis AG
    • 8.6.4.1. Participant's Overview
    • 8.6.4.2. Financial Performance
    • 8.6.4.3. Product Benchmarking
    • 8.6.4.4. Recent Developments
  • 8.6.5. Sanofi
    • 8.6.5.1. Participant's Overview
    • 8.6.5.2. Financial Performance
    • 8.6.5.3. Product Benchmarking
    • 8.6.5.4. Recent Developments
  • 8.6.6. OMRON Corporation
    • 8.6.6.1. Participant's Overview
    • 8.6.6.2. Financial Performance
    • 8.6.6.3. Product Benchmarking
    • 8.6.6.4. Recent Developments
  • 8.6.7. Medline Industries, LP.
    • 8.6.7.1. Participant's Overview
    • 8.6.7.2. Financial Performance
    • 8.6.7.3. Product Benchmarking
    • 8.6.7.4. Recent Developments
  • 8.6.8. GF Health Products, Inc.
    • 8.6.8.1. Participant's Overview
    • 8.6.8.2. Financial Performance
    • 8.6.8.3. Product Benchmarking
    • 8.6.8.4. Recent Developments
  • 8.6.9. DRIVE MEDICAL GMBH & CO. KG
    • 8.6.9.1. Participant's Overview
    • 8.6.9.2. Financial Performance
    • 8.6.9.3. Product Benchmarking
    • 8.6.9.4. Recent Developments
  • 8.6.10. Teva Pharmaceutical Industries Ltd
    • 8.6.10.1. Participant's Overview
    • 8.6.10.2. Financial Performance
    • 8.6.10.3. Product Benchmarking
    • 8.6.10.4. Recent Developments
  • 8.6.11. Aerogen (Stamford Devices Limited Group)
    • 8.6.11.1. Participant's Overview
    • 8.6.11.2. Financial Performance
    • 8.6.11.3. Product Benchmarking
    • 8.6.11.4. Recent Developments
  • 8.6.12. Sensirion AG
    • 8.6.12.1. Participant's Overview
    • 8.6.12.2. Financial Performance
    • 8.6.12.3. Product Benchmarking
    • 8.6.12.4. Recent Developments
  • 8.6.13. PARI Respiratory Equipment, Inc.
    • 8.6.13.1. Participant's Overview
    • 8.6.13.2. Financial Performance
    • 8.6.13.3. Product Benchmarking
    • 8.6.13.4. Recent Developments
  • 8.6.14. Catalent, Inc
    • 8.6.14.1. Participant's Overview
    • 8.6.14.2. Financial Performance
    • 8.6.14.3. Product Benchmarking
    • 8.6.14.4. Recent Developments
  • 8.6.15. Pfizer Inc.
    • 8.6.15.1. Participant's Overview
    • 8.6.15.2. Financial Performance
    • 8.6.15.3. Product Benchmarking
    • 8.6.15.4. Recent Developments
  • 8.6.16. Beurer GmbH
    • 8.6.16.1. Participant's Overview
    • 8.6.16.2. Financial Performance
    • 8.6.16.3. Product Benchmarking
    • 8.6.16.4. Recent Developments